Proton therapy is used to treat cancer and tumours through a beam of protons to irradiate the diseased tissue. It is a type of radiation therapy that uses a particle accelerator to charge protons to treat diseases specially cancer. It is one of the most advanced type of particle therapy available throughout. Proton therapy can be used to treat tumours that are near imperative parts of the body. For example, tumours near the eye, brain, and spinal cord. In proton therapy, there are less chances of harming the healthy, developing tissue so it is used to treat childhood cancers of brain, eye and spinal cord. This therapy may also be used other cancers including lung cancer, liver cancer, spinal and pelvic sarcomas, eye cancer, head and neck cancer, prostate cancer and central nervous system cancers including chordoma, chondrosarcoma, and malignant meningioma.
At present Asia has about 15 proton therapy centres and it is expected that this number will increase to almost double in the coming years. This is because many facilities for proton therapy are either in under-construction or in the planning phase. Japan dominates the Asian proton therapy market and has the second largest market share globally. South Korea is the second largest provider of proton therapy in Asia. China and Korea have been increasing their contribution to the industry every year.
IBA, Varian Medical Systems and Elekta are some of the biggest companies that are present in the proton therapy industry globally.The leading company in Japan for proton therapy is Mitsubishi. However, there are many other companies who have managed to make a mark on the Japanese market like IBA, Hitachi, and Sumitomo etc. China has the largest population in the world and consequently the number of cancer patients is gigantic. This provides a huge market opportunity that has been identified by companies well. IBA already has one operational proton therapy centre in China and four more centres are in development phase. Two proton therapy centres are under development in India and are scheduled to start in 2018 and 2019.
Around 60% of the total world population lives in Asia and it is home to nearly half of the cancer patients. This provides a lot of potential to grow and expand for the proton therapy industry. There is a huge gap between the demand and supply of proton therapy. The cases of cancer have been increasing rapidly and the demand for the therapy is high but the number of patients that can be treated is relatively low due to the limited availability of proton therapy centres. One of the major hindrance in the proton therapy industry is the cost and size of the particle accelerator, synchrotron. It requires high initial investment and is quite outsized too. Many companies have been trying to enlarge accelerators that are smaller. Some of the technologies that are being considered include ultra-compact synchrotrons, linear particle accelerators, super conducting synchrocyclotrons and dielectric wall accelerators.
Topics Covered in The Report
- Asia Proton Therapy Market Research Report
- Asia Proton Therapy Market Size
- Asia Proton Therapy Market
- Asia Proton Therapy Market Structure
- Asia Proton Therapy Output
- Asia Proton Therapy Market Future Outlook
- Asia Proton Therapy Market competition
- Proton therapy Global Market research Report
- Asia Proton Therapy Market future
- Asia Proton Therapy Market growth
- Asia Proton Therapy Market trends
- Asia Proton Therapy Market share
- Asia Proton Therapy Market analysis
- Asia Proton Therapy Market trend
For further reading click on the link below:
Related reports:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249
